Amgen Posts 10% Revenue Hike in Q2 2026
Amgen, a leading biotechnology company, reported a 10% revenue increase in its Q2 2026 results. The company's Chairman and CEO, Bob Bradway, highlighted strong performance across their business, with total revenues reaching $10.1 billion.
The growth was driven by 22 medicines that delivered at least double-digit sales growth, and six key growth drivers that grew 26% year over year, generating nearly 70% of product sales. This success is attributed to the company's efforts to expand its existing portfolio through new indications and advance innovative medicines.
Bradway expressed confidence in Amgen's ability to deliver long-term growth, stating 'we remain confident we can deliver growth well into the next decade.' He credited the company's colleagues and partners around the world for their commitment to patients, which he believes makes this progress possible every day.